CGTX vs. ANIX, CRBP, GALT, ARTV, HLVX, VOR, SKYE, DBVT, CTOR, and ALTS
Should you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Anixa Biosciences (ANIX), Corbus Pharmaceuticals (CRBP), Galectin Therapeutics (GALT), Artiva Biotherapeutics (ARTV), HilleVax (HLVX), Vor Biopharma (VOR), Skye Bioscience (SKYE), DBV Technologies (DBVT), Citius Oncology (CTOR), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry.
Cognition Therapeutics vs.
Cognition Therapeutics (NASDAQ:CGTX) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Anixa Biosciences has higher revenue and earnings than Cognition Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cognition Therapeutics had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 8 mentions for Cognition Therapeutics and 5 mentions for Anixa Biosciences. Cognition Therapeutics' average media sentiment score of 0.48 beat Anixa Biosciences' score of 0.14 indicating that Cognition Therapeutics is being referred to more favorably in the media.
43.3% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by insiders. Comparatively, 25.3% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Cognition Therapeutics presently has a consensus target price of $8.30, indicating a potential upside of 1,848.36%. Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 192.60%. Given Cognition Therapeutics' higher possible upside, equities research analysts clearly believe Cognition Therapeutics is more favorable than Anixa Biosciences.
Anixa Biosciences received 5 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. Likewise, 72.97% of users gave Anixa Biosciences an outperform vote while only 70.97% of users gave Cognition Therapeutics an outperform vote.
Anixa Biosciences' return on equity of -58.55% beat Cognition Therapeutics' return on equity.
Cognition Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
Summary
Anixa Biosciences beats Cognition Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Cognition Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cognition Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CGTX) was last updated on 3/4/2025 by MarketBeat.com Staff
